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aldosterone and stimulates epithelial sodium
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WNK1 belongs to a unique family of SerThr kinases that have
been implicated in the control of blood pressure. Intronic deletions
in the WNK1 gene result in its overexpression and lead to
pseudohypoaldosteronism type II, a disease with salt-sensitive
hypertension and hyperkalemia. How overexpression of WNK1
leads to Na retention and hypertension is not entirely clear.
Similarly, there is no information on the hormonal regulation of
expression of WNK kinases. There are two main WNK1 transcripts
expressed in the kidney: the originally described ‘‘long’’ WNK1 and
a shorter transcript that is specifically expressed in the kidney
(KS-WNK1). The goal of this study was to determine the effect of
aldosterone, the main hormonal regulator of Na homeostasis, on
the transcription of WNK1 isoforms in renal target cells, by using
an unique mouse cortical collecting duct cell line that stably
expresses functional mineralocorticoid receptors. Our results dem-
onstrate that aldosterone, at physiological concentrations, rapidly
induces the expression of the KS-WNK1 but not that of the
long-WNK1 in these cells. Importantly, stable overexpression of
KS-WNK1 significantly increases transepithelial Na transport in
cortical collecting duct cells. Similarly, coexpression of KS-WNK1
and the epithelial Na channel in Fischer rat thyroid epithelial cells
also stimulates Na current, suggesting that KS-WNK1 affects the
subcellular location or activity but not the expression of epithelial
Na channel. These observations suggest that stimulation of KS-
WNK1 expression might be an important element of aldosterone-
induced Na retention and hypertension.
hypertension  collecting duct
H igh blood pressure affects 20–25% of the adult populationin industrialized countries; yet the etiology of the majority
of cases is poorly understood. In recent years, however, the
molecular mechanism of several monogenic forms of hyperten-
sion showing Mendelian inheritance has been identified. Inter-
estingly, the mutations in these forms of hypertension converge
on a common pathway, i.e., the aldosterone-regulated renal
sodium reabsorption. For instance, Liddle’s syndrome, a disease
mimicking hyperaldosteronism, is caused by gain-of-function
mutations in the epithelial sodium channel (ENaC), which leads
to abnormally high renal Na reabsorption, low-renin hyperten-
sion, and hypokalemic alkalosis (1). In contrast, the features of
another autosomal dominant form of familial hypertension,
pseudohypoaldosteronism type II (PHAII) or Gordon’s syn-
drome are more complex than Liddle’s syndrome. In PHAII, the
hypertension is associated with chloride-dependent sodium re-
tention, hyperkalemia, and metabolic acidosis despite normal
glomerular filtration rate (2). PHAII patients are markedly
sensitive to thiazide diuretics (3). Despite the fact that these
features indicate an overactive thiazide-sensitive Na-Cl cotrans-
porter (NCC), no mutations in this transporter have been found
in affected patients.
WNKs (with no lysine [K]) are SerThr kinases that lack a key
lysine in the catalytic domain that is well conserved in other
protein kinases (4). Recently, mutations in WNK1 and WNK4
genes were identified as the cause of PHAII. Both WNK1 and
WNK4 are highly expressed in the renal distal convoluted tubule,
connecting tubule, and cortical collecting duct (CCD) (5).
Oocyte expression studies demonstrated that WT WNK4 inhib-
its the surface expression and thereby the activity of the NCC,
and one of the four missense mutations in WNK4 that cause
human hypertension attenuates this inhibitory effect (6, 7). This
action could explain, at least in part, the increased salt retention
and resulting hypertension in PHAII (3). The observations that
WNK4 is strongly expressed in nephron segments other than the
distal convoluted tubule (the exclusive site of NCC expression)
and in extrarenal tissues (5, 8), suggest that the NCC is not the
sole target of WNK4 action. Indeed, recent studies by Lifton and
coworkers (9) demonstrated that when coexpressed in Xenopus
oocytes, WNK4 inhibits the surface expression of several renal
transporters including the secretory K channel, ROMK, and
the Clbase exchanger SLC26A6 (8). These effects might con-
tribute to the hyperkalemia and acidosis in PHAII. In addition,
Madin–Darby canine kidney (MDCK) cells overexpressing a
disease-causing mutant WNK4 have increased paracellular Cl
permeability (10). These studies strongly implicate WNK4 as a
multifunctional regulator of Na, Cl, and K transport.
Much less is known about the function and regulation of
WNK1. Unlike the missense mutations in WNK4 that affect
the coding region, hypertension-causing mutations in WNK1
are large intronic deletions that result in increased WNK1
expression, suggesting that in contrast to WNK4, the WT
WNK1 stimulates Na retention. Consistent with an important
role in regulating blood pressure, recently it was shown that
WNK1-deficient mice display a significant decrease in blood
pressure (11).
The mechanism by which increasedWNK1 expression leads to
hypertension is unknown. In oocytes, WNK1 has no direct effect
on NCC activity, but it attenuates the inhibitory effect of WNK4
(7), suggesting that gain-of-function mutations in WNK1, by
opposing the inhibitory effect of WNK4 on NCC, could con-
tribute to Na retention. However, because WNK1 is widely
expressed (5, 12), it is quite possible that it has additional effects
on Na and Cl transport besides affecting NCC. For example, its
expression in the collecting duct raises the possibility that it
could regulate ENaC. Whether WNK1 also opposes the inhib-
itory action of WNK4 on other transporters such as ROMK and
SLC26A6 is unknown.
Both in human and in mouse, multiple WNK1 mRNA species
are expressed that arise by alternative promoter usage and
splicing (13, 14). Most intriguing is the observation that the
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expression pattern of the different transcripts is tissue- and
developmental stage-specific. In the kidney, in addition to the
originally described ‘‘long’’ WNK1 (L-WNK1) (4), the most
prominently expressed WNK1 is a shorter transcript (13, 14).
Surprisingly, this kidney-specific WNK1 (KS-WNK1) is initiated
at an alternative promoter and lacks the first four exons that
include the kinase domain of WNK1 (13).
Although the central role of aldosterone in the control of renal
Na transport has been known for decades, the exact molecular
steps of this regulation are just beginning to be uncovered.
Because both gain-of-function mutations in the aldosterone
pathway as well as increased WNK1 expression (in PHAII) lead
to hypertension, in this study we tested the effect of aldosterone
on the expression of the two WNK1 isoforms in the main
mineralocorticoid target cells, i.e., renal collecting duct cells. We
report here that aldosterone rapidly induces the expression of
the KS-WNK1 in an unique mouse CCD cell line that expresses
functional mineralocorticoid receptors (MRs). Furthermore, we
show that ectopic expression of KS-WNK1 in mammalian epi-
thelial cells results in a significant increase of ENaC-associated
Na current.
Methods
Generation of M1 Cell Lines Stably Expressing MRs or the KS-WNK1.
The rat MR was subcloned into the retroviral vector pLNCX,
and retroviruses were generated by transient transfection into
amphotropic Phoenix cells by using Lipofectamin PLUS reagent
(Invitrogen). M1 cells were cultured and infected with retrovi-
ruses as described (15), and clones stably expressing MR were
selected with G418 (500 gml). These cell lines will be referred
to as M1-MR cells. Individual clones were expanded and tested
for 3H-aldosterone binding. To determine a number of MRcell,
parent M1 cells, and M1-MR clones were incubated at a
saturating concentration (4 nM; determined in pilot experi-
ments) of [1,2-3H]aldosterone [Amersham Pharmacia; specific
activity 36 Cimmol in the presence (nonspecific binding) or
absence (total binding) of a 1,000-fold excess of unlabeled
aldosterone].
Because a full-length KS-WNK1 clone is not available, to
generate cell lines stably expressing the KS-WNK1, first wemade
a chimeric construct encoding exon 4A of the human KS-WNK1
(13) fused to the rat WNK1 (4) at the PacI site in exon 5 (distal
from exon 4, the sequences of the KS-WNK1 and L-WNK1 are
identical). We used an EST clone that contains the full exon 4A
of human KS-WNK1 (GenBank accession no. AI768512) and
PCR-amplified a 650-nt fragment by using KS-WNK1-specific
primer located in the 5-UTR region (5-CTG TTT AAG CTT
CCA CCA TGG ATA TTA AAA AGA AAG ATT TTT
GC-3), which generates a HindIII site and a vector primer
(5-GGG TTT TCC CAG TCA CGA CG-3). The 650-bp
product was digested with PacI and HindIII and ligated into rat
WNK1 (a gift of Melanie Cobb, University of Texas Southwest-
ern Medical Center, Dallas), which was previously subcloned
into a modified retroviral vector. M1 cells were infected with
retroviruses and clones stably expressing KS-WNK1 selected
based on G418 resistance. In addition to individual clones, we
generated three lines of pooled clones, each one containing
500 individual clones. The expression of the KS-WNK1 was
verified by RT-PCR by using primers specific for the 3 end.
M1-MR Cell Culture and Electrophysiology. Parent M1 cells and
M1-MR clones were seeded onto Millicell permeable mem-
branes (Millipore) at a density of 4  105 cells per filter. After
seeding, cells were bathed in complete PC1 medium (BioWhit-
taker, Walkersville, MD) with 5% FBS until they formed
confluent monolayers (3–4 days). Transepithelial voltage
(VTE) and resistance (RTE) values were determined with an
epithelial voltohmmeter (World Precision Instruments, Sara-
sota, FL), and equivalent short-circuit current was (Isc) calcu-
lated. We previously demonstrated that, in M1 cells, Isc mainly
represents transepithelial sodium current (15). This was verified
by treating cells with 1 M amiloride from the apical side, which
resulted in an almost total elimination of the lumen negative VTE
and associated Isc.
To determine the effects of aldosterone, after reaching con-
fluence, cells were maintained in steroid-free medium (DMEM/
F125% FBS stripped twice with charcoal15 mMHepes2 mM
glutamineantibiotics) for 2 days, then treated with 0.1–10 nM
aldosterone for different periods. The receptor specificity of
aldosterone was determined by testing its effects in the presence
of 1 M ZK91587, a specific MR antagonist or 1 M 486, a
glucocorticoid receptor (GR)-antagonist.
The effect of protein synthesis inhibitors was tested by pre-
incubating M1-MR cells for 30 min with vehicle, 5 gml
cycloheximide (CHX), or 10 M anisomycin. The phosphati-
dylinositol 3-kinase (PI3-kinase) inhibitor LY294002 was added
at 50 M with or without 1 nM aldosterone, and cells were
incubated for an additional 4 h before RNA was prepared.
Semiquantitative RT-PCR. To determine the relative abundance of
the KS-WNK1 and the L-WNK1 mRNAs in control and corti-
costeroid-treated M1 and M1-MR cells, we used semiquanti-
tative RT-PCR as described earlier (16–18). Cells were main-
tained in steroid-free medium for 48 h, treated with 1 nM
aldosterone or 5 nM dexamethasone for 30 min to 24 h, and then
lysed in TRI-reagent. Total RNA was prepared, and cDNA was
synthesized as described (16–18). Sense (5-CCG AAA CCA
CTG TGG AAG TCG C-3) and antisense (5-ATC TAC CGT
CGA GTG ACC AGT G-3) PCR primers for the mouse
L-WNK1 and sense (5-TTG CCT TTT CTG ATG GAT T-3)
and antisense (5-TCC TTT TGA GAA CAG CAG C-3)
primers for the mouse KS-WNK1 were selected based on the
published sequences (14). PCR reactions were performed with
four different amounts (20, 5, 1.25, and 0.3125 ng) of cDNA
originating from control or steroid-treated cells. After a 2-min
denaturation at 96°C, PCR for the L-WNK1 was carried out for
27 cycles (96°C for 45 sec, 55°C for 45 sec, and 72°C for 1 min).
For the KS-WNK1 PCR, we used touchdown conditions: five
cycles each at annealing temperature of 59°C, 55°C, and 52°C,
and then 15 cycles at annealing temperature of 49°C. The identity
of the PCR products was verified by sequencing. The relative
abundance of -actin mRNA in each sample was determined by
using primers and conditions as described (16–18). cDNA
samples derived from control and steroid-treated cells were
always amplified simultaneously. The PCR products were sep-
arated on a 5% polyacrylamide gel, stained in ethidium bromide,
and quantitated with a FluorImager 575 (Molecular Dynamics).
The slope of the amount of PCR products vs. amount of template
cDNA was derived by linear regression. These values were
normalized for the amount of -actin mRNA. SGK1 mRNA
levels were determined by RT-PCR as in ref. 18.
Expression of ENaC and KS-WNK in Fischer Rat Thyroid (FRT) Cells.
FRT epithelia were cultured on permeable filter supports (Mil-
licell PCF, 0.4-m pore size, 12-mm diameter) in F-12 Coon’s
medium (Sigma), 100 unitsml penicillin, and 100 gml strep-
tomycin, as described (19). One day after seeding, the cells were
transfected with human , , and  ENaC (WT or Y644A,
Y620A, Y627A) (in pMT3, 0.07 g of each) along with KS-WNK1
(0–0.8 g). Total cDNA was held constant by using GFP cDNA.
Amiloride-sensitive short-circuit current was measured 2 days
after transfection in modified Ussing chambers (Warner Instru-
ments, Hamden, CT). The apical and basolateral membranes
were bathed in 135 mMNaCl, 1.2 mMCaCl2, 1.2 mMMgCl2, 2.4
mM K2HPO4, 0.6 mM KH2PO4, and 10 mM Hepes (pH 7.4) at








37°C. Amiloride-sensitive current was determined by the addi-
tion of 100 M amiloride to the apical bathing solution.
Results
Biochemical and Functional Characterization of theM1-MR Cell Lines.
M1 cells that originate from mouse CCD (20), like most other
cultured CCD cell lines (21–26), do not express functional MRs.
Therefore, to study the physiological effects of aldosterone
mediated through MRs and not the ubiquitously expressed GR,
we first generated M1 cells stably expressing MRs. We isolated
several clonal M1 cell lines expressing 16,000–70,000 high-
affinity (Kd in the nanomolar range) MRscell (the parent M1
cells did not have measurable MR binding). It should be noted
that the reported number of MRscell in vivo is10,000 (27, 28).
Thus, M1MR cells are moderately overexpressing MR, com-
pared with physiological aldosterone target cells. For further
studies, we selected four clonal cell lines with different MR
numbers. All four M1-MR cell lines, but not the parent M1
cells, responded to physiological concentrations of aldosterone
(1 nM) with a 2- to 4-fold increase in the expression of SGK1,
an early aldosterone-induced gene in the CCD (18, 29). Data for
parent M1 cells and M1-KS-WNK1 clonal line 2 are shown in
Fig. 1. These data also indicate that the effect is not mediated
through GRs that are expressed in parent M1 cells. The effect
of aldosterone on SGK1 gene expression was very similar in each
cell line tested, and there was no obvious correlation between the
magnitude of the effect and the number of MRs per cell (data
not shown).
To verify that the stably expressed MRs are fully functional,
we tested the effect of aldosterone on transepithelial Na
transport (Isc). Aldosterone, at physiological concentrations,
significantly increased Isc in a time-dependent fashion in all cell
lines. Data for clonal cell line 1 are shown in Fig. 2. The increase
in Isc was completely blocked by the apical addition of 1 M
amiloride (data not shown), indicating that it was due to Na
currents through ENaC. Aldosterone stimulation of Isc was
observed after 4 h, and this effect was maintained for the
duration of the experiment (48 h). The effect was near maximal
at 1 nM of aldosterone (Fig. 2B) and was completely prevented
by the MR-antagonist ZK 91857 (100 nM) but not by the
GR-antagonist, RU 486 (data not shown), indicating that this
effect is specifically mediated via the MR.
Aldosterone Increases the Expression of the KS-WNK1 Isoform. There
are twomainWNK1 transcripts expressed in both the human and
mouse kidney. The larger (10-kb) transcript has a wider
distribution and is expressed at lower levels (13, 14). The shorter
and more abundant (8.5-kb) transcript KS-WNK1 is specifi-
cally expressed in the distal portion of the nephron (14).
Remarkably, KS-WNK1 lacks the N-terminal region of WNK1
that includes the kinase domain. First, we examined the expres-
sion of these two WNK1 transcripts in M1-MR cells by using
primer pairs specific for the two transcripts. These pilot studies
revealed that both WNK1 transcripts are expressed in M1-MR
cells.
We next examined the effect of 1 nM aldosterone on the
expression of the WNK1 transcripts. This low concentration of
aldosterone occupies only the MR but not the GR. As shown in
Fig. 3A, aldosterone rapidly increased the expression of the
KS-WNK1 in clonal cell line 1. The increase was observed as
early as 30 min after hormone treatment, and mRNA levels
remained elevated for the duration of the experiment. This effect
Fig. 1. Effect of aldosterone on SGK1 mRNA expression in parent M1 cells
and in cell lines stably expressing MR. Aldosterone (1 nM) significantly induces
SGK1 expression in M1-MR clone 2 (P 0.05 vs. control, one-tailed unpaired
t test) but not in parent M1 cells (n  3). Cells were grown for 48 h in
steroid-free medium, and then medium was changed to the same (control) or
supplemented with 1 nM aldosterone, for 4 h.
Fig. 2. Aldosterone increases transepithelial Na current (Isc) in M1-MR cells.
(A) M1-MR clone 1 cells (n 11) and parent M1 cells (n 4) were grown on
Millicell filters, and Isc values were determined after 24-h incubation without
(CTR, empty bars) or with 1 nM aldosterone (striped bars). ***, P  0.001 vs.
control cells (one-tailed t test). Values are means  SE. (B) Concentration
dependence of the effect of aldosterone. Values were obtained after 24 h. P
0.05 for each concentration vs. control (no aldosterone) by using one-tailed
unpaired t test.
Fig. 3. Aldosterone increases the expression of the KS-WNK1 transcript in
M1-MR cells. (A) Time course of aldosterone effect in M1-MR clone 1. (B) The
effect of a 4-h incubation in clone 2. KS-WNK1 mRNA levels were determined
by using semiquantitative RT-PCR in cells at different times after treatment
with 1 nM aldosterone or vehicle. mRNA levels were normalized for the levels
of-actin mRNA, determined from the same samples.n3 for each time point
for clone 1, n 2 for clone 2. *, P 0.05; **, P 0.01, one-tailed t test, vs. cells
not treated with aldosterone. (C) Dexamethasone (5 nM) increases the ex-
pression of KS-WNK1 isoform in M1-MR clone 1 (4-h incubation).n 4, *, P
0.05, one-tailed t test.
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could be observed in allM1-MR cell lines tested; data for clonal
line 2 are shown in Fig. 3B.
Because in the CCD most genes that are induced by the MR
can also be up-regulated by the GR (18, 21, 25, 29, 30), we next
tested the effects of dexamethasone (5 nM), a synthetic glu-
cocorticoid that saturates the GR but does not bind to the MR
at such low concentration. As expected, dexamethasone also
induced the expression of the KS-WNK1; the effect of a 4-h
treatment is shown in Fig. 3C.
The rapid time course of aldosterone induction of KS-WNK1
suggested that it is probably due to direct transcriptional regu-
lation through binding of MRs to a glucocorticoid response
element (GRE) in the promoter of the KS-WNK1. Nevertheless,
we considered the possibility that SGK1, which is induced by
aldosterone as early as 15–30 min (18, 29) and is known to
stimulate ENaC-mediated Na transport, could indirectly me-
diate KS-WNK1 induction by aldosterone. Because activity of
the PI3-kinase pathway is necessary for SGK function, we tested
the effect of aldosterone in the presence of the specific PI3-
kinase inhibitor LY294002. This inhibitor, however, did not
prevent the induction of KS-WNK1 (Fig. 4). To examine whether
de novo synthesis of other aldosterone-induced proteins is nec-
essary for KS-WNK1 induction, we determined the effects of
aldosterone in the presence of two structurally different inhib-
itors of protein synthesis (CHX and anisomycin). Data in Fig. 4
indicate that when cells were treated with aldosterone plus these
protein synthesis inhibitors, the levels of KS-WNK were still
significantly higher than those in untreated control cells and
were not significantly different from levels obtained with aldo-
sterone alone. It has to be noted, however, that one of the
inhibitors, CHX, in itself increased KS-WNK1 mRNA levels
(P 0.05 vs. control samples, and KS-WNK1 mRNA levels were
not significantly induced by aldosterone when CHX was present
(P  0.07 as compared to CHX alone). This apparent induction
of KS-WNK1 by CHX is probably due to the well known
‘‘superinduction’’ phenomenon. Therefore, although the rapid
time course, the presence of a GRE in the KS-WNK1 promoter
and data obtained with anisomycin suggest that the effect of
aldosterone is direct, based on the results obtained with CHX,
a partial indirect effect cannot be excluded.
Aldosterone and Dexamethasone Do Not Induce the Expression of the
L-WNK1. Next, we asked the question whether the aldosterone
induction is specific for the KS-WNK1 or is the L-WNK1 also
up-regulated. By using primers specific for the third exon in the
mouse L-WNK1 (which is absent in the KS-WNK1), we
determined expression levels of the L-WNK1 isoform from the
same samples used for measuring the KS-WNK1 transcript
levels. Surprisingly, neither aldosterone (Fig. 5) nor dexameth-
asone (data not shown) changed the expression of the L-
WNK1 isoform significantly at either early or late time points.
Thus, the steroid regulation seems to be specific for the
KS-WNK1 isoform.
Expression of the KS-WNK1 Isoform Increases Transepithelial Na
Current in M1 Cells. To determine the functional consequences
of up-regulating the levels of KS-WNK1, we have generated
several M1 lines overexpressing KS-WNK1. The expression of
the KS-WNK1 construct was verified by RT-PCR by using
sequence-specific primers present only in the construct but not
in the endogenous mouse KS-WNK1 (data not shown). We
selected three lines consisting of pooled clones (each contain-
ing 500 clones) as well as two individual clonal cell lines for
further studies. To compare the effects of KS-WNK1 on
electrophysiological parameters, parent M1 cells and cell lines
stably expressing KS-WNK1 were seeded at the same cell
densities on Millicell permeable membranes and maintained in
complete growth medium. After reaching conf luence, RTE and
VTE were determined and Isc values were calculated. As shown
in Fig. 6A, all cell lines expressing the KS-WNK1 had signif-
icantly higher Isc values than the parent M1 cells when cells
were grown in a complete growth medium containing growth
factors and steroids. Fig. 6B illustrates Na current values of
a combined pool of all cell lines vs. parent M1 cells when grown
in steroid-free medium. Under these conditions, Na current
also was significantly higher in cells expressing the KS-WNK1
than in parent M1 cells. In a few cultures, we also determined
the effect of activation of endogenous GRs on Isc. As expected,
dexamethasone (100 nM) increased Isc in parent M1 cells
(from 2.93  1.69 to 6.01  2.7 Ampcm2 in steroid-free
medium vs. DEX; n  3, P  0.05) as well as in KS-WNK1-
expressing M1 cells (from 7.82  2.2 to 10.6  5 Ampcm2;
n  6; P  0.05). This response to DEX is not due a further
elevation of the ectopically expressed WNK1 (which is not
driven by a steroid-responsive promoter) but is probably
mediated through other steroid-regulated pathways.
KS-WNK1 Stimulates ENaC in FRT Epithelia. To further test the
hypothesis that KS-WNK1 regulates ENaC, we coexpressed
them in FRT epithelia, which lack endogenous Na currents
(19). Transfection of FRT cells with , , and  ENaC generated
Fig. 4. The effect of PI3-kinase and protein synthesis inhibition on the
induction of KS-WNK1 by aldosterone. M1-MR clone 1 cells were grown in
steroid-free medium for 2 days and then preincubated for 30 min with vehicle
CHX (5gml) or anisomycin (aniso; 10M). Aldosterone (1 nM) was given (or
not) at 30 min, and cells were incubated for an additional 4 h before RNA was
prepared. KS-WNK1 and -actin mRNA levels were determined by RT-PCR. *,
P  0.05, **, P  0.01, ***, P  0.001 vs. control, two-tailed unpaired t test.
Comparisons were also made between values for each treatment obtained
with and without aldosterone;P0.05 for vehicle vs. aldosterone;P0.05 for
LY vs. LY aldosterone; P 0.07 for CHX vs. CHX aldosterone; P 0.05 for
anisomycin vs. anisomycin  aldosterone (using one-tailed unpaired t tests).
The values of KS-WNK1 mRNA levels in the presence aldosterone alone were
not significantly different from those in cells incubated with aldosterone and
LY or CHX or anisomycin (using two-tailed unpaired t tests). LY, LY294002.
Fig. 5. Aldosterone does not induce the expression of the L-WNK1 transcript
in. M1-MR clone 1 cells were incubated with vehicle or 1 nM aldosterone for
the indicated times. Values shown are normalized for control cultures.n3–5.
As a comparison, the levels of KS-WNK1 mRNA, determined from the same
samples, are also shown. *, P  0.05 vs. control by using one-tailed unpaired
t test.








amiloride-sensitive transepithelial Na current (Fig. 7A). Co-
transfection with KS-WNK1 increased ENaC current in a dose-
dependent manner (Fig. 7), indicating that KS-WNK1 stimulates
ENaC.
ENaC surface expression is controlled in part by proline
tyrosine (PY) motifs located in the C terminus of each ENaC
subunit (reviewed in refs. 31–33). These motifs are binding sites
for Nedd4-2, an E3 ubiquitin-protein ligase that targets ENaC
for degradation. We asked whether the PY motifs contribute to
ENaC regulation by KS-WNK1.When wemutated the PYmotifs
to Ala in all three subunits (Y644A, Y620A, and Y627A),
KS-WNK1 did not increase ENaC current (Fig. 7B). Thus, ENaC
regulation by KS-WNK1 depends on the ENaC PY motifs.
Discussion
The main findings of this study are that (i) aldosterone, at
physiological concentration, rapidly and specifically induces the
expression of the KS-WNK1 isoform in renal CCD cells; and (ii)
overexpression of the KS-WNK1 in mammalian epithelial cells
results in a significant increase in transepithelial Na transport
by stimulating ENaC activity. These data suggest that the
induction of KS-WNK1 transcription might be part of the
mechanism by which aldosterone increases Na reabsorption in
the collecting duct.
WNK kinases have been recently implicated in the pathogen-
esis of hypertensive hyperkalemia associated with PHAII (Gor-
don’s syndrome; ref. 5). WNKs are highly expressed in the distal
convoluted and connecting tubules as well as the collecting duct
system of the kidney (5) where the final regulation of salt balance
occurs. However, the mechanism of action of WNKs remains
largely unknown. Because the same phenotype results from
gain-of-function mutations in WNK1 and loss-of-function mu-
tations in WNK4 (5), it is likely that both genes act in the same
pathway but have opposing actions.
Because one of the hallmarks of PHAII is marked thiazide
sensitivity, one likely mechanism that could lead to increased
distal Na reabsorption in this disease is overactivity of NCC.
Indeed, recent studies showed that in Xenopus oocytes WNK4
inhibits NCC activity whereas WNK1 relieves this inhibitory
effect resulting in higher thiazide-sensitive Na transport (6, 7).
Deletions in the first intron in the WNK1 gene in affected
patients lead to elevated expression of WNK1 (5). The excess
WNK1 could neutralize the inhibitory effect of WNK4 on NCC,
which in turn leads to increased Na reabsorption in the distal
nephron.
The role of the KS-WNK1 in the regulation of renal ion
transport has not been previously investigated. Because hyper-
aldosteronism results in Na retention and hypertension, we
hypothesized that at least part of the effect of aldosterone could
be mediated by increasing the transcription of KS-WNK1. The
striking differences in tissue- and cell-specific expression of the
different WNK1 transcripts raise the possibility that these iso-
forms have different actions and are differentially regulated.
Indeed, our results indicate that the KS-WNK1 and the more
broadly expressed L-WNK1 isoforms are differentially regulated
by corticosteroids in renal CCD cells. These twoWNK1 isoforms
are generated via alternative promoter usage (13), and the
promoter of the KS-WNK1 transcript contains a putative GRE
(identified by the TESS transcription factor binding site search
program) immediately 5 from the first ATG (13). On the other
hand, transcription factor binding site computer programs failed
to identify classical GREs in the L-WNK1 promoters (13). Thus,
the rapid induction of KS-WNK1 by aldosterone is probably a
direct effect through binding of MRs to the GRE (13).
What is the biological function of the KS-WNK1 isoform?
Our findings that it is induced by physiological concentrations
of aldosterone and increases Na transport in CCD cells
Fig. 7. Transepithelial Na current in FRT epithelia coexpressing ENaC and
KS-WNK1. FRT epithelia were transfected with ENaC (WT or Y644A, Y620A,
Y627A, 0.07 g of each subunit) and KS-WNK1 (0–0.8 g, total cDNA held
constant with GFP cDNA). (A) Representative short-circuit current tracings for
ENaC coexpressed with GFP (‘‘	KS-WNK1’’) or KS-WNK1 (0.8 g). Amiloride
(100 M) was added to apical bathing solution as indicated by bar. (B) Plots of
amiloride-sensitive short-circuit current (relative to 0 g KS-WNK1 for each
group) vs. quantity of KS-WNK1 cDNA for WT ENaC and Y644A, Y620A, Y627A
(‘‘Y-A’’) (mean  SEM, n  11–19; asterisks indicate P  0.02 vs. 0 g of
KS-WNK1).
Fig. 6. Stable expression of the KS-WNK1 increases transepithelial Na
current in M1 cells. (A) Individual clonal lines (clones 1 and 2) as well as cell lines
containing pooled clones (1, 2, and 3) were grown in complete growth
medium (PC1) to confluence on Millicell membranes. *, P 0.05, **, P 0.01
vs. parent M1 cells, two-tailed unpaired t test. (B) Values for KS-WNK1-
expressing cells shown were pooled from the two clonal cell lines and mixed
clonal lines 1–3. Cells were grown in complete medium for 3 days after
reaching confluence, and then medium was changed to DMEMF12 contain-
ing 5% 2x-stripped FBS (steroid-free, SF) and electrical measurements taken 24
and 48 h later, n  12 for parent M1; n  23 for KS-WNK1 cells, *, P  0.001,
vs. parent M1 cells, two-tailed unpaired t test.
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indicate that it might be an important regulator of ENaC
function. This isoform seems to be physiologically more rel-
evant for Na transport than the L-WNK1, which is expressed
in many other tissues that do not participate in the regulation
of Na balance. At this point, we can only speculate on the
possible mechanisms of its action. Because the KS-WNK1
lacks the kinase domain, its mechanism of action probably
involves protein–protein interactions rather than SerThr
phosphorylation. The unique sequence in KS-WNK1 (exon
4A) contains a Cys-rich region. Perhaps this region alters the
function of a protein involved in Na transport by forming
intermolecular disulfide bonds. That kinase activity of WNKs
is not always required for biological action is supported by the
recent observation that the inhibitory action of WNK4 on
ROMK is independent of its kinase activity (9).
It is interesting to note that recently WNK1 was shown to
modulate the activity of synaptotagmins that are important
regulators of membrane trafficking and vesicle fusion, suggesting
that WNK1 might regulate ion transport by increasing the
number of transporters in the plasma membrane (34). We
speculate that the KS-WNK1might have similar effects. Another
potential target for KS-WNK1 is WNK4, as predicted from
previous work (7). Because M1 cells express significant levels of
WNK4 (A.N.-F.-T., unpublished data), in theory, KS-WNK1
could counteract the effects of WNK4 thereby stimulating Na
reabsorption in the distal nephron. Whether there is a direct
interaction between KS-WNK1 and WNK4 has not yet been
studied.
Because Nedd4-2 is a key regulator of ENaC (35–37), another
possible target for KS-WNK1might be Nedd4-2. Consistent with
this possibility is our finding that the ENaC PY motifs are
required for KS-WNK1 to stimulate ENaC in FRT epithelia.
Importantly, mutations in the ENaC PY motifs also cause
hypertension (Liddle’s syndrome). In theory, KS-WNK1 could
also increase Na transport by increasing the transcription or
synthesis of ENaC. The findings, however, that KS-WNK1
enhances ENaC currents when ENaC is ectopically expressed in
FRT cells and that ENaC mutations abolish this effect argue
against this mechanism. We hypothesize that WNK1 mutations
increase renal Na reabsorption and cause hypertension through
two mechanisms: (i) increased activity of the thiazide-sensitive
NCC in the distal convoluted tubule, which is suggested by
oocyte expression experiments (7); and (ii) increased Na reab-
sorption in the CCD via ENaC (data not shown).
In summary, our results show that aldosterone rapidly induces
the expression of the KS-WNK1 transcript. Even more impor-
tantly, overexpression of KS-WNK1 in two types of mammalian
epithelia results in a significant elevation of transepithelial Na
transport. Thus, KS-WNK1 might be an important element of
aldosterone-induced Na retention and hypertension.
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